APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST

Exclusion Criteria

• •1. Undergone major surgery or major trauma within 28 days before first dose or a diagnostic biopsy within 14 days before first dose.
• •2. Received systemic antitumor drugs, including investigational drugs.
• •3. Received radiotherapy within 14 days before first dose.
• •4. Previous treatment with FAK inhibitors.
• •5. Have tumors at positions other than existing ovarian cancer or of other histological types within 3 years before first dose.
• •6. Known active central nervous system (CNS) metastases and/or cancerous meningitis.
• •7. Major cardiovascular and cerebrovascular disease occurred within 6 months before first dose.
• •8. Patients with pleural effusion, pericardial effusion, or ascites requiring puncture, drainage, or having received drainage within 1 month before first dose.
• •9. Malabsorption syndrome, or inability to take medications orally.
• •10. Severe gastrointestinal disease.
• •11. Any serious or uncontrolled systemic disease; Various chronic active infections.
• •12. Allergy to APG-2449 or PLD and its drug components.
• •13. Previous cumulative doses of anthracyclines ≥550 mg/m\^2.
• •14. Patients using a moderately potent CYP3A4, CYP2C9, or CYP2C19 inhibitor/inducer or P-gp inhibitor within a week before first dose. Patients using CYP3A4 substrates and the drugs of a narrow treatment window within a week before first dose.
• •15. Other factors that, in the investigator's judgment, should prevent the patient from entering the study.